WARMINSTER, Pa., March 02, 2021 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that William Collier, Arbutus’ President and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference held virtually from March 9-10, 2021.

A webcast of the virtual presentation will be available starting at 7:00 am (EST) on March 9, 2021, and can be accessed through the Investors section of Arbutus’ website at

www.arbutusbio.com

or directly at

Webcast

.   An archived replay of the webcast will be available on the Company’s website after the conference.

About Arbutus

Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company primarily dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19). For more information, visit


www.arbutusbio.com


.

Contact Information

Investors and Media

William H. Collier

President and CEO

Phone: 267-469-0914

Email:

[email protected]

Pam Murphy

Investor Relations Consultant

Phone: 267-469-0914

Email:

[email protected]